Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/10/?d=1Neue Studien: Europe PMCdeSternoclavicular joint involvement in psoriatic arthritis: a hidden indicator of disease severity.https://www.psoriasis-news.de/articles.html/1_articles/sternoclavicular-joint-involvement-in-psoriatic-arthritis-a-hidden-indicator-of-disease-severity-r341/Weiterlesen

]]>341Tue, 25 Nov 2025 19:50:44 +0000Comparing the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin for psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/comparing-the-effectiveness-and-drug-persistence-of-methotrexate-cyclosporine-and-acitretin-for-psoriasis-r340/No abstract supplied.

Weiterlesen

]]>340Tue, 25 Nov 2025 19:50:44 +0000Dupilumab-Induced Psoriasis in a Patient With Chronic Rhinosinusitis With Nasal Polyps: A Case Reporthttps://www.psoriasis-news.de/articles.html/1_articles/dupilumab-induced-psoriasis-in-a-patient-with-chronic-rhinosinusitis-with-nasal-polyps-a-case-report-r339/No abstract supplied.

Weiterlesen

]]>339Tue, 25 Nov 2025 19:50:44 +0000Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals.https://www.psoriasis-news.de/articles.html/1_articles/is-cumulative-life-course-impairment-considered-in-psoriasis-management-a-multinational-survey-of-people-with-psoriasis-and-healthcare-professionals-r338/IntroductionDelays remain in patients receiving effective treatment strategies that have potential to clear their skin of psoriasis, improve their quality of life (QoL) and change the psoriatic disease course, which, if uncontrolled, can irreversibly alter an individual's life course (i.e. cumulative life course impairment [CLCI]). This study explored current international awareness and consideration of the potential impact of psoriasis over the life course within clinical assessments and decisions about its management.

Methods

Cross-sectional surveys collated insights from people with psoriasis and healthcare professionals (HCPs) treating psoriasis (dermatologists and primary care physicians [PCPs]) across 29 countries.

Results

Data were collected from 487 people with psoriasis, 574 dermatologists and 618 PCPs. Despite people with psoriasis highlighting a range of daily activities that are 'very frequently' or 'always' affected by their psoriasis, 37% were never or rarely asked by their HCPs how the disease affects their life. Fewer than half of people with psoriasis had a high understanding of the potential future impact of psoriasis (or CLCI-contributing factors), and 44% were unaware that clear/almost clear skin is now a realistic treatment target. Almost half of HCPs considered psoriasis to be of early onset when it presented at ≤ 15 years of age. Despite HCP awareness of the impact of psoriasis on QoL, many of the contributing factors to CLCI were not addressed routinely in clinical practice nor considered when deciding on treatment; 40% of dermatologists set treatment goals (such as clear skin/almost clear skin/target Dermatology Life Quality Index [DLQI]) sometimes, less frequently, or not at all.

Conclusions

Misalignment exists in the experience of people living with psoriasis versus its assessment in clinical practice. Support is needed for assessment and monitoring of elements that may contribute to CLCI in clinical practice worldwide, to guide early psoriasis treatment decision-making to mitigate the risk for CLCI. Infographic available for this article. INFOGRAPHIC.

Weiterlesen

]]>338Tue, 25 Nov 2025 19:50:44 +0000Familial prevalence of psoriasis in patients with multiple sclerosis – results from an Australian surveyhttps://www.psoriasis-news.de/articles.html/1_articles/familial-prevalence-of-psoriasis-in-patients-with-multiple-sclerosis-results-from-an-australian-survey-r337/No abstract supplied.

Weiterlesen

]]>337Tue, 25 Nov 2025 19:50:44 +0000Targeting the epigenetic regulator bromodomain-containing protein 4 by BRD4 siRNA lipoplexes and PFI-1 in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/targeting-the-epigenetic-regulator-bromodomain-containing-protein-4-by-brd4-sirna-lipoplexes-and-pfi-1-in-psoriasis-r336/Weiterlesen

]]>336Sat, 01 Nov 2025 16:29:54 +0000Coexistence of Psoriasis and Pemphigus: A Case Report of Pemphigus Vulgaris With a Review of the Literature.https://www.psoriasis-news.de/articles.html/1_articles/coexistence-of-psoriasis-and-pemphigus-a-case-report-of-pemphigus-vulgaris-with-a-review-of-the-literature-r335/Weiterlesen

]]>335Sat, 01 Nov 2025 16:29:54 +0000The causal relationship between uveitis and psoriatic arthritis: A bidirectional Mendelian randomisation study.https://www.psoriasis-news.de/articles.html/1_articles/the-causal-relationship-between-uveitis-and-psoriatic-arthritis-a-bidirectional-mendelian-randomisation-study-r334/Weiterlesen

]]>334Sat, 01 Nov 2025 16:29:54 +0000Regulatory T Cells: Subtle and Promising Achilles' Heel of Psoriasis - Atherosclerosis Comorbidity.https://www.psoriasis-news.de/articles.html/1_articles/regulatory-t-cells-subtle-and-promising-achilles-heel-of-psoriasis-atherosclerosis-comorbidity-r333/Weiterlesen

]]>333Sat, 01 Nov 2025 16:29:54 +0000[Medical health apps for psoriasis and psoriatic arthritis].https://www.psoriasis-news.de/articles.html/1_articles/medical-health-apps-for-psoriasis-and-psoriatic-arthritis-r332/Weiterlesen

]]>332Sat, 01 Nov 2025 16:29:54 +0000Medication utilization patterns among patients with rheumatoid arthritis and coexisting autoimmune conditions.https://www.psoriasis-news.de/articles.html/1_articles/medication-utilization-patterns-among-patients-with-rheumatoid-arthritis-and-coexisting-autoimmune-conditions-r331/Weiterlesen

]]>331Sat, 01 Nov 2025 16:29:54 +0000Infections during childhood as predisposing factors to develop Psoriasis Vulgaris into early adulthood.https://www.psoriasis-news.de/articles.html/1_articles/infections-during-childhood-as-predisposing-factors-to-develop-psoriasis-vulgaris-into-early-adulthood-r330/Weiterlesen

]]>330Sat, 01 Nov 2025 16:29:54 +0000Understanding the drivers of BASDAI and back pain scores in psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/understanding-the-drivers-of-basdai-and-back-pain-scores-in-psoriatic-arthritis-r329/ObjectivesThe Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used to assess axial disease activity in psoriatic arthritis (PsA). However, 5 of its 6 questions reflect general disease activity rather than axial-specific symptoms. We aimed to evaluate the performance of BASDAI and its back pain subscore in assessing axial disease in PsA.

Methods

Patients with BASDAI scores were identified from a longitudinal PsA cohort initiated in 1978. Axial disease was defined radiographically. Trends in BASDAI and back pain scores were compared between patients with and without axial involvement. Associations of total BASDAI and back pain subscore with axial disease were assessed using univariable and multivariable linear mixed models in the entire cohort and stratified subgroups.

Results

Of 1059 patients, 449 (42.4%) had axial and 610 (57.6%) had peripheral disease only. The mean age was 44.4 years (SD 12.8), and 55.9% were male. No difference in the BASDAI and back pain trends was observed between the axial and peripheral disease groups. Axial involvement was not associated with total BASDAI scores (β = -0.14, 95% CI -0.05 to 0.33). However, it was associated with a small, yet significant increase in back pain subscore (0.30, 0.06-0.55). Both BASDAI and back pain scores were associated with active peripheral joints, enthesitis, dactylitis, age, Psoriasis Area and Severity Index, and inversely with male sex. These associations were consistent across axial and peripheral disease subgroups.

Conclusions

BASDAI and its back pain subscore are influenced by peripheral musculoskeletal and skin disease activity in PsA, limiting their utility for assessing axial activity.

Weiterlesen

]]>329Sat, 01 Nov 2025 16:29:54 +0000Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-and-safety-of-risankizumab-in-genital-or-scalp-psoriasis-in-the-unlimmited-phase%C2%A04-randomized-clinical-trial-at-week%C2%A016-r328/IntroductionPsoriasis (PsO) in the genital and scalp areas is associated with increased patient burden and impact on quality of life. Effective treatments for PsO in these high-impact areas are essential, though patients are frequently excluded from both biologic clinical trials and treatment because of their often low overall affected body surface area (BSA) despite the disproportionate impact of PsO on their quality of life. Recent guidance also considers these patients as candidates for advanced therapies. Here, we compare the efficacy and safety of risankizumab, an interleukin-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis, versus placebo in the treatment of PsO in the genital or scalp region.

Methods

UnlIMMited (NCT05969223) is an ongoing phase 4, multicenter, randomized, double-blind, placebo-controlled study for adult patients with moderate-to-severe genital or scalp PsO in patients with < 10% BSA or ≥ 10% BSA involvement. Two parallel studies were conducted with study-G assessing genital PsO and study-S assessing scalp PsO. Patients were randomized 1:1 within each study to receive either 150 mg risankizumab or placebo at weeks 0 and 4. The primary endpoints for the studies were the achievement of static Physician's Global Assessment - Genital (sPGA-G) 0/1 for study-G and scalp Investigator Global Assessment (IGA) 0/1 for study-S, both assessed at week 16. Secondary endpoints are also reported at week 16 in each study assessing skin clearance, symptom resolution, and impact on quality of life. Safety was reported through the first 16 weeks.

Results

At week 16, in both studies, a significantly higher proportion of patients receiving risankizumab achieved the primary endpoints compared with placebo. In study-G, 69.1% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved sPGA-G 0/1 (P < 0.0001). In study-S, 60.8% of patients receiving risankizumab versus 13.0% of patients receiving placebo achieved scalp IGA 0/1 (P < 0.0001). No new safety signals were identified.

Conclusion

These results demonstrate that risankizumab is effective in the treatment of genital and scalp psoriasis at week 16, with no new safety signals identified.

Trial registration number

ClinicalTrials.gov identifier NCT05969223.

Weiterlesen

]]>328Thu, 30 Oct 2025 08:59:40 +0000Changes in weight associated with tumor necrosis factor inhibition in psoriatic arthritis: results from a retrospective cohort study.https://www.psoriasis-news.de/articles.html/1_articles/changes-in-weight-associated-with-tumor-necrosis-factor-inhibition-in-psoriatic-arthritis-results-from-a-retrospective-cohort-study-r327/ObjectivesSeveral studies have reported weight gain with tumor necrosis factor inhibitors (TNFi) in psoriatic disease. However, such analyses have not accounted for the natural propensity for weight gain over time. We aimed to investigate whether therapy with TNFi in psoriatic arthritis (PsA) patients is associated with a change in the rate of weight gain post-treatment initiation.

Methods

We included patients with at least two weight measurements prior to, and after commencing TNFi and used change point analysis to assess the differences in the rate of weight gain based on the mean slope before and after TNFi initiation, adjusting for clinically relevant variables.

Results

Of 234 patients eligible for inclusion, 62.8% were males. At the first clinic visit, the mean (standard deviation) age was 41.8 (12.2) years, while the mean disease duration was 5.1 (6.8) years. The mean weight immediately prior to TNFi use was 83.8 (17.2) kg, while that at the last available visit on TNFi was 86.4 (18.6) kg (p = 0.39), over an average period of 7.9 (5.8) years. The mean values of the pre- and post-TNFi slopes were 0.52 (95% confidence interval [CI] 0.18-0.87) and 0.28 (95% CI - 0.05-0.61), respectively (p = 0.09); thus, there was a trend towards lower rate of weight gain followed the initiation of TNFi therapy.

Conclusions

TNFi treatment is not associated with an increase in weight above the expected gain in PsA. Prior trajectory of weight gain with age must be considered while studying the impact of treatment on weight.

Key points

• TNFi are commonly used in the management of psoriatic disease and may influence body weight. • TNFi treatment is not associated with a significant increase in body weight when accounting for the trend of weight gain with time. • The trends in weight change may differ between etanercept and monoclonal antibody TNFi agents.

Weiterlesen

]]>327Thu, 30 Oct 2025 08:45:38 +0000The concept of severity in psoriatic arthritis: a scoping review of the literature.https://www.psoriasis-news.de/articles.html/1_articles/the-concept-of-severity-in-psoriatic-arthritis-a-scoping-review-of-the-literature-r326/ObjectiveThe concept of severity in psoriatic arthritis (PsA) remains inconsistently defined, often conflated with disease activity. This scoping review aimed to explore how severity has been defined in the PsA literature and to identify criteria used to characterize severe disease.

Methods

A scoping review was conducted in April 2025 following PRISMA-ScR guidelines. PubMed was searched for English-language articles from the last 25 years, alongside abstracts from major rheumatology conferences. Eligible studies had to explicitly define or discuss PsA severity. Articles focusing solely on activity, isolated disease manifestations, or other conditions were excluded. Data were extracted on the type of article, definitions of severity, and criteria used.

Results

Of 4,014 records screened, 32 studies met inclusion criteria. Definitions of severity varied widely and were categorized into imaging (e.g., erosions), clinical (e.g., dactylitis, joint counts), and functional (e.g., HAQ-DI scores) criteria. The most commonly used indicators were structural damage, polyarticular involvement, dactylitis, arthritis mutilans, and validated composite indices such as CPDAI. Only a few studies incorporated functional impairment or patient-reported outcomes. While some guidelines, including GRAPPA and ACR/NPF, proposed multidomain frameworks, a standardized definition remains lacking.

Conclusion

The concept of PsA severity has evolved beyond mere disease activity to encompass long-term outcomes, radiographic damage and overall disease burden. However, considerable heterogeneity persists across studies, reflecting the complexity of PsA. A standardized, multidimensional definition of severity, distinct from disease activity, would enhance patient stratification, guide treatment decisions, and support clinical research.

Weiterlesen

]]>326Thu, 30 Oct 2025 08:45:38 +0000Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/immunopeptidome-analysis-reveals-serpinb3-as-an-autoantigen-driving-eczematized-psoriasis-r325/H17) cells, with several clinical subtypes. While self-reactive immune responses have been observed, the role of autoantigens in Pso remains unclear. Using immunopeptidomics, we identified serpin family B member 3 (SERPINB3) and SERPINB4 as candidate autoantigens in Pso skin. In a mouse model, the SERPINB3 ortholog Serpinb3b enhanced inflammation, promoted tissue-resident memory T cells, and skewed immunity toward a TH2 phenotype. In humans, SERPINB3 reactivity was specifically associated with "eczematized psoriasis" (EczPso), a subtype marked by TH2/TH17 immune signatures. SERPINB3 protein was enriched in EczPso lesions and highly secreted by keratinocytes under combined TH2/TH17 stimulation. Lesional T cells from EczPso-but not from eczema or classical plaque Pso-proliferated in response to SERPINB3 and induced EczPso-like features in a skin model. Our findings identify SERPINB3 as an autoantigen driving a distinct Pso subtype, supporting more precise diagnosis and therapy.

Weiterlesen

]]>325Thu, 30 Oct 2025 08:45:38 +0000Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors.https://www.psoriasis-news.de/articles.html/1_articles/expert-opinion-report-on-the-challenges-in-the-management-of-psoriatic-arthritis-in-united-arab-emirates-a-focus-on-interleukin-17-inhibitors-r324/PurposeTo seek recommendations from a panel of experts in psoriatic arthritis (PsA) on the current management challenges, local practices, and role of interleukin (IL)-17 inhibitors in the United Arab Emirates (UAE) using evidence from phase III trials as background.

Methods

Nine rheumatologists who treat PsA in the UAE completed a structured survey and attended a meeting to discuss topics/issues identified in the survey. A literature search was performed to identify phase III randomized trials of IL-17 inhibitors available in the UAE for PsA.

Results

There was general agreement among the panel on the most common PsA domains presenting in patients (most commonly psoriasis [75-95% of patients], peripheral arthritis [50-90%], and enthesitis [40-90%]). In general, IL-17 inhibitors were among the preferred treatment options for managing PsA, particularly for patients with axial-, enthesitis-, or psoriasis-related symptoms. Current unmet needs and challenges included a lack of disease awareness among the general population and other healthcare professionals; the lack of a single medication to cover all domains/comorbidities; and lack of universal insurance coverage. The panel had experienced success with the IL-17 inhibitors ixekizumab and secukinumab, with many citing no preference for either agent. The literature search identified publications relating to 10 key phase III clinical trials of IL-17 inhibitors.

Conclusion

The panel advocates for the use of the domain-based Group for Research and Assessment of Psoriasis and Psoriatic Arthritis treatment recommendations and generally considers IL-17 inhibitors (ixekizumab or secukinumab) as the preferred treatment options for managing PsA.

Weiterlesen

]]>324Thu, 30 Oct 2025 08:45:38 +0000Dermatologic and Metabolic Benefits of Semaglutide in Psoriasis with Obesity: A Six-Month Prospective Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/dermatologic-and-metabolic-benefits-of-semaglutide-in-psoriasis-with-obesity-a-six-month-prospective-cohort-study-r323/BackgroundPsoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have shown metabolic and anti-inflammatory effects, but their impact on psoriasis in non-diabetic patients with obesity remains unclear.

Objective

To evaluate the effects of a six-month semaglutide treatment on psoriasis severity and clinical, metabolic, inflammatory, and psychosocial parameters in patients with psoriasis and obesity.

Methods

In this prospective cohort study, 43 patients received weekly semaglutide along with lifestyle counseling. Psoriasis severity (PASI), quality of life (DLQI), depressive symptoms (BDI), nutritional ultrasound, and biochemical markers were assessed baseline and after six months. Correlations between PASI improvement (ΔPASI) and baseline variables and their changes were analyzed, adjusting for age and weight loss.

Results

After six months, participants showed significant reductions in PASI (-48%), BMI, preperitoneal and superficial fat, along with improvements in DLQI, BDI, and metabolic markers. Baseline disease severity, depressive symptoms, insulin resistance, and preperitoneal fat were negatively associated with PASI improvement. These associations remained significant after adjustment (e.g., HOMA-IR, r = -0.82; preperitoneal fat, r = -0.66). ΔPASI was most strongly correlated with reductions in superficial fat (r = 0.89), DLQI (r = 0.55), and BDI (r = 0.51). Changes in BMI and glycemic markers were not significantly associated after adjustment.

Conclusions

In patients with psoriasis and obesity, semaglutide improves both skin disease and systemic health. The clinical benefit appears associated with specific fat loss and psychosocial improvement, beyond overall weight reduction.

Weiterlesen

]]>323Thu, 30 Oct 2025 08:45:38 +0000Psoriasis-like inflammation induces structural and functional changes in mitochondria.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-like-inflammation-induces-structural-and-functional-changes-in-mitochondria-r322/Weiterlesen

]]>322Thu, 30 Oct 2025 08:45:38 +0000Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/biologic-therapies-and-major-cardiovascular-events-in-psoriasis-updated-systematic-review-and-meta-analysis-r321/IntroductionCardiovascular disease is a leading co-morbidity in psoriasis patients. The cutaneous benefits of biologic therapies for severe plaque psoriasis are well-established, but the impact of biologics on major adverse cardiovascular events (MACE) in psoriatic patients requires further elucidation. This study aimed to investigate the impact of biologic therapies on the risk of MACE in patients with chronic plaque psoriasis.

Methods

We conducted a systematic review and meta-analysis on 10 May 2022, using Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR) and EMBASE databases for relevant studies. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) methodology was applied, and all studies were critically appraised. All studies selected for inclusion were randomised control trials (RCTs) that contained data on MACE and compared licensed biologic therapies with placebo or other biologics in adults with moderate-severe plaque psoriasis.

Results

The search of the databases revealed 36 papers (reporting on 43 RCTs) which met the inclusion criteria. No statistically significant difference in the risk for MACE between biologic therapies and placebo was found [Peto odds ratio (POR) 1.26, 95% confidence interval (CI) 0.53-3.01, P = 0.59]. A comparison of specific types of biologics also revealed no significant effect in adult patients with moderate-to-severe plaque psoriasis: tumour necrosis factor (TNF)-alpha inhibitors (adalimumab, infliximab, etanercept) (POR 1.13, 95% CI 0.29-4.32 P = 0.86), interleukin (IL)-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) (POR 0.60, 95% CI 0.16-2.25, P = 0.45); IL 12/23 inhibitors (usetekinumab) (POR 3.80, 95% CI 0.37-39.44, P = 0.26) and IL-23 (guselkumab, risankizumab, tildrakizumab) (POR 1.75, 95% CI 0.25-12.43 P = 0.58).

Conclusions

Anti-psoriatic biologics were not associated with an increased risk of MACE in psoriasis patients. Given that most included RCTs were of relatively short duration, longer-term studies and post-marketing surveillance are needed to clarify the cardiovascular safety profile of biologic therapies. Further large-scale studies with extended follow-up are warranted.

Study registration

This study was prospectively registered on PROSPERO (identification number CRD42022325792).

Weiterlesen

]]>321Thu, 30 Oct 2025 08:45:38 +0000Utility and Limitations of Large Language Models to Simplify Online Content on Generalized Pustular Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/utility-and-limitations-of-large-language-models-to-simplify-online-content-on-generalized-pustular-psoriasis-r320/Weiterlesen

]]>320Thu, 30 Oct 2025 08:45:38 +0000Pre-eclampsia is more common in women with active psoriatic arthritis in pregnancy: a population-based study.https://www.psoriasis-news.de/articles.html/1_articles/pre-eclampsia-is-more-common-in-women-with-active-psoriatic-arthritis-in-pregnancy-a-population-based-study-r319/ObjectiveTo investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, preterm birth and fetal growth in women with psoriatic arthritis (PsA).

Methods

Data from a Norwegian nationwide register (RevNatus) were linked with data from the Medical Birth Registry of Norway (MBRN). Cases were singleton births in women with PsA with available disease activity assessment (n=109) included in RevNatus 2010 to 2019. Singleton births registered in MBRN during the same decade served as population controls (n=575 798). Disease activity was assessed by Disease Activity Score based on 28 joints using C reactive protein (DAS28-CRP) in 2nd and 3rd trimester. Active PsA was defined as DAS28-CRP≥2.6 (n=34) and inactive PsA as DAS28-CRP<2.6 (n=75).

Results

Pre-eclampsia was most frequent in women with active PsA (3/34, 8.8%), with a risk difference of 6.1% (95% CI 0.3 to 20.3, p=0.036) compared with population controls (2.6%). Gestational hypertension occurred in 2/34 (5.9%) of women with active PsA, with a risk difference of 4.2% (95% CI 0.0 to 17.4, p=0.065) compared with population controls (1.7%). Pre-eclampsia and gestational hypertension occurred in similar proportions in women with inactive PsA (1.3%, p=0.59 and 2.7%, p=0.24, respectively) and population controls. The occurrence of preterm birth and abnormal fetal growth was comparable in cases and population controls.

Conclusion

Hypertensive disorders of pregnancy occurred more often in women with active, but not inactive PsA. We found no increased risk for preterm birth or abnormal fetal growth in women with PsA.

Weiterlesen

]]>319Thu, 30 Oct 2025 08:45:38 +0000Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials.https://www.psoriasis-news.de/articles.html/1_articles/response-to-tofacitinib-in-patients-with-psoriatic-arthritis-and-probable-anxietydepressive-disorder-a-post-hoc-analysis-of-phase-3-trials-r318/IntroductionMental health status potentially influences treatment responses. The effect of probable anxiety and/or depressive disorder (pADD) on tofacitinib efficacy, patient-reported outcomes (PROs), and safety in psoriatic arthritis (PsA) was assessed.

Methods

This was a post hoc analysis of two phase 3 trials in patients with PsA receiving tofacitinib, adalimumab, or placebo, and an open-label extension study. Outcomes were stratified by presence/absence of baseline pADD (Short Form-36 Health Survey [SF-36] Mental Component Summary score ≤ 38/ > 38). American College of Rheumatology ≥ 20%, ≥ 50%, and ≥ 70% (ACR20/50/70) responses, remission and/or low disease activity based on Psoriatic Arthritis Disease Activity Score and Disease Activity Index for Psoriatic Arthritis score, minimal disease activity, and PROs (pain/Health Assessment Questionnaire-Disability Index/fatigue) were assessed through month 36. Safety was assessed through month 12.

Results

Overall, 323/706 (45.8%) patients had baseline pADD; of these, a higher proportion were female versus male (61.9% vs. 38.1%). Numerically higher proportions achieved efficacy/PRO responses with tofacitinib versus placebo, regardless of baseline pADD (month 3). Responses with tofacitinib were generally similar in patients with versus without baseline pADD (e.g., month 3 ACR20 responses: 54.0% vs. 58.5%); some differences were observed at later time points (e.g., month 9 minimal disease activity: 25.0% vs. 43.8%; p < 0.05). Baseline pADD did not appear to affect the incidence of treatment-emergent adverse events.

Conclusions

Baseline pADD was frequent in patients with PsA initiating tofacitinib and was higher in female patients. Tofacitinib-treated patients had generally similar efficacy/safety outcomes, regardless of baseline pADD. Some differences in efficacy outcomes were noted in the longer term (9-12 months). Limitations of this study include small numbers in some analyses and use of SF-36 as pADD proxy.

Trial registration

ClinicalTrials.gov: NCT01877668; NCT01882439; NCT01976364.

Weiterlesen

]]>318Thu, 30 Oct 2025 08:45:38 +0000Bioinformatics analyses of comorbid mechanisms between psoriasis and type 2 diabetes mellitus.https://www.psoriasis-news.de/articles.html/1_articles/bioinformatics-analyses-of-comorbid-mechanisms-between-psoriasis-and-type-2-diabetes-mellitus-r313/Weiterlesen

]]>313Thu, 30 Oct 2025 08:31:24 +0000